How MHRA Identifies and Addresses Data Integrity Issues in UK Clinical Trials

Data integrity has become one of the most scrutinised areas in Medicines and Healthcare products Regulatory Agency (MHRA) inspections of UK clinical trials. In recent years, multiple inspection reports and regulatory updates have highlighted that weaknesses in trial documentation, audit trails, and oversight continue to undermine data reliability. For sponsors, contract research organisations (CROs), and NHS Trusts acting as investigator sites, data integrity failures can result in inspection findings, protocol deviations, or delays in clinical development programmes.

This article uses a problem–solution lens to explore the most common data integrity issues observed by MHRA, explain their root causes, and present strategies to strengthen compliance in UK trials.

Background and Regulatory Framework

MHRA Expectations

MHRA applies the principles of Good Clinical Practice (GCP), ICH E6(R2), and national regulations to ensure that trial data are accurate, complete, and attributable. In particular, MHRA emphasises the ALCOA+ principles: data must be Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available.

Legislative Basis

The Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) provide the statutory basis for MHRA’s inspection powers. Inspections may target sponsors, CROs, and investigator sites, with a focus on whether electronic and paper records meet regulatory standards.

Problem–Solution Analysis of MHRA Data Integrity Findings

Problem 1 — Incomplete or Missing Trial Master File (TMF) Records

Observation: MHRA inspections frequently cite incomplete TMFs, missing approvals, or inconsistent document versions.
Root Cause: Weak sponsor oversight of CRO-managed eTMFs and lack of version control practices.
Solution: Implement validated electronic TMF systems, enforce version tracking, and schedule regular TMF QC checks.

Problem 2 — Poor Audit Trail Practices in Electronic Systems

Observation: Audit trails were not activated or were missing critical metadata, preventing full reconstruction of data histories.
Root Cause: Use of unvalidated systems or reliance on non-compliant software for data capture.
Solution: Validate all electronic systems per Part 11/GCP, ensure audit trails are active from study start, and periodically review them.

Problem 3 — Backdating and Retrospective Data Entry

Observation: Investigators or coordinators entered data retrospectively without proper justification, raising questions of accuracy.
Root Cause: Site staff overwhelmed by NHS workload pressures and lack of timely source data entry.
Solution: Train staff on contemporaneous entry, use electronic health record integration where possible, and monitor entry timelines.

Problem 4 — Source Data Discrepancies

Observation: Discrepancies between patient medical records and case report forms (CRFs) were noted.
Root Cause: Manual transcription errors and poor reconciliation practices.
Solution: Introduce double data entry for critical fields, reconcile EHRs with CRFs routinely, and adopt centralised monitoring dashboards.

Problem 5 — CRO Oversight Failures

Observation: Sponsors failed to adequately oversee CROs managing data, resulting in missing SAE reports or incomplete datasets.
Root Cause: Over-reliance on CRO assurances without independent sponsor QC.
Solution: Strengthen sponsor oversight with documented audits, regular KPI reviews, and clear delegation agreements.

Problem 6 — NHS Trust Capacity Issues

Observation: NHS sites faced staff shortages, leading to delayed SAE reporting and incomplete patient notes.
Root Cause: Competing healthcare priorities reduced research bandwidth.
Solution: Allocate dedicated research nurses and coordinators, funded through NIHR CRN or sponsor support.

Best Practices for Data Integrity in UK Trials

• Adopt ALCOA+ principles as a training cornerstone for all site staff.
• Validate all IT systems and ensure audit trail functionality.
• Conduct sponsor-led TMF QC reviews every quarter.
• Implement risk-based monitoring focused on data-critical endpoints.
• Strengthen communication between sponsors, CROs, and NHS Trusts.

Scientific and Regulatory Evidence

• MHRA GCP Inspection Metrics Reports (annual publications)
• Medicines for Human Use (Clinical Trials) Regulations 2004
• ICH E6(R2) – Good Clinical Practice
• MHRA Guidance on Data Integrity (2018)
• EMA Reflection Papers on TMF and Electronic Systems

Special Considerations

• Oncology Trials: High-volume data and multiple endpoints demand rigorous audit trail oversight.
• Pediatric Trials: Documentation must include caregiver-reported outcomes, creating additional data points to verify.
• Rare Diseases: Small datasets increase the impact of individual data errors, requiring extra QC.
• Decentralised Trials: Data collected remotely introduces cybersecurity and validation challenges under MHRA scrutiny.

When Sponsors Should Seek Regulatory Advice

• When adopting novel data capture tools such as wearables or ePRO platforms.
• If CRO oversight processes fail or inspection findings raise systemic gaps.
• For trials with highly vulnerable populations requiring enhanced monitoring.
• When transitioning from paper-based to fully electronic TMFs or CRFs.

FAQs

1. What are the most common MHRA findings on data integrity?

Incomplete TMFs, missing audit trails, backdated entries, and weak CRO oversight are frequently observed.

2. Does MHRA accept retrospective data entry?

Only if fully documented, justified, and traceable. Unexplained backdating is a major finding.

3. How can NHS Trusts improve data integrity?

By dedicating research staff, integrating EHRs with CRFs, and ensuring contemporaneous entry practices.

4. Are electronic systems mandatory in UK trials?

No, paper can still be used, but electronic systems must be validated and Part 11-compliant if used.

5. What role do CROs play in UK data integrity?

CROs manage data processes, but sponsors remain ultimately accountable for compliance.

6. How does MHRA view decentralized trial data?

With caution. Systems must demonstrate reliability, security, and full audit trail functionality.

7. What happens if MHRA finds critical data integrity issues?

Possible outcomes include inspection findings (critical/major), trial suspension, or rejection of data in marketing applications.

Conclusion

Data integrity issues remain a top focus of MHRA inspections in UK clinical trials. By understanding common pitfalls, addressing root causes, and adopting robust oversight mechanisms, sponsors, CROs, and NHS Trusts can safeguard trial credibility. A proactive, problem–solution approach ensures that data remain reliable, regulatory-compliant, and fit for global submissions.